A Case of Relapsing Tubulointerstitial Nephritis with Antimitochondrial M2 Antibody Accompanied by Pulmonary Involvement

Aya Nakamori, Fuyuko Akagaki, Yoshito Yamaguchi and Toshihiro Sugiura

Abstract:
We herein report a 50-year-old woman who suffered from tubulointerstitial nephritis with antimitochondrial M2 antibody, distal renal tubular acidosis, and Fanconi syndrome. Our case also had interstitial pneumonia. After initially successful glucocorticoid therapy, tubulointerstitial nephritis and interstitial pneumonia relapsed. After the second successful round of glucocorticoid therapy, tubulointerstitial nephritis relapsed again and responded to glucocorticoid and azathioprine. This case might indicate (1) the association between pulmonary involvement and tubulointerstitial nephritis with antimitochondrial antibodies and (2) the need for a maintenance dose of glucocorticoid and immunosuppressants in tubulointerstitial nephritis with antimitochondrial antibodies.

Key words: tubulointerstitial nephritis, antimitochondrial antibodies, pulmonary involvement, immunosuppressant, distal renal tubular acidosis, Fanconi syndrome

Introduction
The first case of tubulointerstitial nephritis (TIN) with primary biliary cholangitis (PBC) was reported in 1987 (1). Since then, cases of TIN with PBC and/or antimitochondrial antibodies (AMAs) have been reported to have similar clinical features of appearing predominantly in women, high serum IgM levels, AMA positivity, distal renal tubular acidosis, proximal renal tubular dysfunction, and responsiveness to glucocorticoid therapy (1-5).

However, some of those cases relapsed after glucocorticoid withdrawal or did not respond to glucocorticoids at all (1, 2). The standard therapy of TIN with AMAs has not been established yet. While TIN with AMAs can be complicated with other systematic diseases, such as Sjögren’s syndrome (4), pulmonary involvement per se has not received much attention in TIN with AMAs.

Case Report
A 50-year-old woman was referred to the Department of Nephrology and Pulmonology in our hospital because of proteinuria and abnormal chest X-ray findings. She suffered from bone pain and dry cough. She had undergone fiberoptic bronchoscopy at another hospital about eight years earlier, but the findings were not specific, although we did not have an opportunity to obtain the results in detail. She had none of the following: dyspnea, fine crackles, skeletal deformities, chronic diarrhea, growth retardation, and Raynaud’s phenomenon. She had a 2.5-pack-year history of smoking and had quit smoking 10 years ago. She consumed a modest amount of alcohol occasionally. She had no history of radiation exposure, other fume/dust inhalation, drug abuse, being exposed to heavy metals, or recent medication. She had no family history of kidney disease, but one of her grandfathers had had diabetes mellitus. Her height was 149.7 cm, and she weighed 42.3 kg. Her blood pressure was 104/70 mmHg.
**Kidney disease**

The initial bloodwork findings were as follows: estimated glomerular filtration rate (eGFR) 57.2 mL/min/1.73 m², urine protein 1.4 g/gCr, urine β2 microglobulin (U-β2MG) 14,774 μg/L, urine pH 7.5, positive urinary anion gap (34 mEq/L), high fractional excretion of uric acid (FEUA) (34.1%), high fractional excretion of potassium (FEK) (12.0%), normoglycemic glycosuria. An arterial blood gas analysis revealed metabolic acidosis (pH 7.323, HCO₃⁻ 12.0%), normoglycemic glycosuria. An arterial blood gas analysis revealed metabolic acidosis (pH 7.323, HCO₃⁻ 19.6 mEq/L) with a normal anion gap (9.4 mEq/L) (Table). Computed tomography (CT) showed left kidney stones (Fig. 1a).

A histological analysis of the kidney showed 12 glomeruli, 7 of which had global sclerosis. Lymphocytes and CD 138-positive plasma cells had infiltrated into the interstitial compartment and between tubules. No other specific changes, such as mesangial cell proliferation, mesangial matrix expansion, or mesangial expansion, were evident (Fig. 2). IgG- and IgM-positive cells were not detected by the immunoenzyme method with formalin-fixed paraffin-embedded sections (Fig. 3). An immunofluorescence analysis showed no deposits of IgG, IgA, IgM, C3, C4, or fibrinogen using fresh-frozen sections. Electron microscopy showed no basement membrane changes, dense deposits, fibrils, or mitochondrial alteration.

**Pulmonary involvement**

Arterial PO₂ was 69.6 mmHg. PCO₂ was 39.0 mmHg, which was higher than expected (about 35 mmHg). Incomplete respiratory compensation indicated that she also had respiratory acidosis with a wide alveolar-arterial oxygen difference (A-aDO₂) (31.4 mmHg). CT showed bilateral multifocal consolidations (Fig. 1b-d). Fiberoptic bronchoscopy was not performed a second time for the histopathological analysis of the lung, at her request.

**Other results**

The IgM level was high (630 mg/dL), and the alkaline phosphatase (ALP) level was 725 IU/L. The bone mineral density at the distal forearm was 0.294 g/cm²; the young adult mean was 61%. Both SS-A and SS-B were negative. While the Rose Bengal tests and Schirmer’s tests in both eyes were positive, she did not have any other ophthalmologic disorders. Neither a lip biopsy nor salivary gland scintigraphy showed any apparent abnormalities. She did not meet the diagnostic criteria of Sjögren’s syndrome (6-8).

Given the above, she was diagnosed with TIN, distal renal tubular acidosis (RTA), Fanconi syndrome, and interstitial pneumonia at this time. Both osteomalacia and osteoporosis were suspected, although a bone biopsy and bone scintigraphy were not performed.

**Clinical course**

Oral prednisolone therapy (30 mg/day) was initiated with alendronate sodium hydrate. Her acidosis was adjusted with oral sodium bicarbonate. After several months, her eGFR had increased to 84.2 mL/min/1.73 m²; her serum phosphorus had increased to 3.4 mg/dL, her ALP had decreased to 112 IU/L, her U-β2MG had decreased to 9,305 μg/L, and her IgM had decreased to 235 mg/dL (Fig. 4). Both the bone pain and dry cough were relieved. The bilateral multifocal pulmonary shadows had almost vanished (Fig. 1e). The dose of prednisolone was gradually reduced, and prednisolone administration ended after about 1.5 years.

However, gradually, she developed hypokalemia (3.1 mEq/L), so she started to take potassium L-aspartate. Her eGFR decreased to 31.7 mL/min/1.73 m², serum phosphorus decreased to 1.1 mg/dL, ALP increased to 356 IU/L, and U-β2MG increased to 61,513 μg/L with a high CRP level (6.17 mg/dL). She also had to start potassium citrate-sodium citrate dehydrate to ameliorate her acidosis. She came to suffer bone pain and dry cough again, along with a fever. Chest CT showed bilateral lung infiltrates (Fig. 5a-c). The second round of oral prednisolone therapy (20 mg/day) was started about 3.5 years after the end of the first round. After a couple of weeks, her eGFR increased to 49.7 mL/min/1.73 m²; her serum phosphorus increased to 3.3 mg/dL, her ALP decreased to 181 IU/L, her U-β2MG decreased to 19,336 μg/L (Fig. 3), and her CRP returned to 0.03 mg/dL. The bilateral pulmonary infiltrates almost disappeared (Fig. 5d). Her bone pain, dry cough, and fever were ameliorated. The dose of prednisolone was gradually tapered, and the prednisolone therapy was halted after about four months due to concerns of glucocorticoid-induced osteoporosis.

Again, her eGFR eventually decreased to 27.3 mL/min/1.73 m² and her serum phosphorus level to 1.9 mg/dL. After starting oral alfalcacidol, the phosphorus level increased slightly to 2.5 mg/dL before gradually declining again to 1.6 mg/dL. The percent tubular re-absorption of phosphate (TRP) was 43.4%, and the tubular maximum of phosphate (TmP/GFR) was 0.95 mg/dL. The ALP level increased to 673 IU/L, the U-β2MG level to 64,978 μg/L, and the urine protein level to 2.6 g/gCr. She had to take more sodium bicarbonate and more potassium citrate-sodium citrate dihydrate to resolve her metabolic acidosis. The total amount of alkali consumed reached 2.3 mmol/kg/day, which was more than the amount required to treat distal RTA in adults (9).

After adjusting her metabolic acidosis by the oral administration of sodium bicarbonate for 2 weeks, the fractional excretion of bicarbonate was 8.0%, which was considered sufficient for the diagnosis of a less severe type of proximal RTA (10). With alkali supplementation, she required more potassium L-aspartate supplementation (18.0 mEq/day) to avoid further hypokalemia (serum potassium 3.3 mEq/L). The urine pH was 8.5 with a positive urinary anion gap (88.2 mEq/L), high FEUA (75.6%), high FEK (105.1%), and normoglycemic glycosuria (casual blood glucose 93 mg/dL, hemoglobin A1c 5.4%, urine sugar 696 mg/dL). In addition, generalized aminoaciduria was observed. Antimitochondrial M2 antibody was positive (141 U/mL) with a high level of IgM (637 mg/dL). Her liver function was normal, and abdominal ultrasonography did not show any signs of
Table. Laboratory Test Findings.

| Test                        | Before Treatment | Before Starting the Third Treatment | Before Starting the Treatment | Before the Treatment | Before Starting the Third Treatment |
|-----------------------------|------------------|--------------------------------------|-----------------------------|----------------------|-------------------------------------|
| White Blood Cells           | 52.7x10^9/μL     | 58x10^9/μL                           | 7.1 g/dL                    | 7.7 g/dL             | cryoglobulins                       | ND                                  |
| Neu                         | 47.8%            | 48.6%                                | 4.2 g/dL                    | 4.3g/dL              | free light chain λκ                  | ND 0.75                            |
| Ly                          | 35.9%            | 38.1%                                | 12.7 mg/dL                  | 14.3 mg/dL           | M protein                            | -                                   |
| Mon                         | 5.5%             | 5.7%                                 | 0.83 mg/dL                  | 1.57mg/dL*           | ANA speckled pattern                 | 1:40*                               |
| Eo                          | 10.2%*           | 6.4%                                 | cGFR                        | 57.2 mL/min.173m2*   | ANA cytoplasmic pattern              | 1:40*                               |
| Ba                          | 0.6%             | 1.2%                                 | UA                          | 1.5 mg/dL*           | SS-A Ab                              | ≤7.0μ/mL ND                         |
| Red Blood Cells             | 417x10^9/μL      | 357x10^9/μL                          | AST                         | 25 IU/L              | SS-B Ab                              | ≤7.0μ/mL ND                         |
| Hb                          | 12.8 g/dL        | 11.4 g/dL                            | ALT                         | 33 IU/L              | antimitochondrial pattern            | ND                                  |
| Ht                          | 40.2%            | 36.5%                                | ALP                         | 725 IU/L*            | TSH                                  | 0.82μIU/mL ND                      |
| platelet                    | 22.1x10^9/μL     | 23.3x10^9/μL                         | ALP-2 34%                   | 673 IU/L*            | free T4                              | 0.97ng/dL 1.01ng/dL                |
| PTT                         | 25.5 sec         | 27.0 sec                             | T-Bil                       | 0.8mg/dL             | pH                                   | 7.5*                                |
| arterial blood gas (at rest)|                 |                                       |                             |                      |                                      | 8.5*                                |
| HCO3^-                      |                  |                                       |                             |                      |                                      |                                     |
| POCO                        | 39.0 nmHg        | ND                                   | LDL-C                       | 95mg/dL              | α1-glob                              | 11.0% ND                           |
| PO2                         | 69.9 nmHg*       | ND                                   | Na                          | 140nmEq/L            | α2-glob                              | 23.2% ND                           |
| HCO3^-                      | 19.6 mEq/L*      | ND                                   | K                           | 3.7mEq/L             | β2-glob                              | 22.4% ND                           |
| A-AD2O                      | 31.4 nmHg*       | ND                                   | CL                          | 111nmEq/L*           | γ-glub                                | 14.1% ND                           |
| SpO2                        | 94.50%           | ND                                   | Ca                          | 8.7mg/dL             | Sugar                                 | 2*                                  |
| HBs Ag                      | 0.00 IU/mL       | ND                                   | CRP                         | 0.01mg/dL            | Red Blood Cells                      | 1.3 /HPF 1.2 /HPF                   |
| HCV Ab - II                 | 0.07 S/CO        | ND                                   | GLU                         | 95mg/dL              | White Blood Cells                    | 2.9/HPF 2.4/HPF                      |
| Hbs Ab                      | ND               | 0.1 mL/μL                           | HbAlc (NGSP)                | 5.0%                 | Granular casts                       | +*                                  |
| Hbc Ab                      | ND               | 0.05 S/CO                           | Magnesium                   | 2.0mg/dL             | Epithelial cell casts                 | +*                                  |
| HIV-Ab                      | ND               | 0.1 S/CO                            | Aluminum                   | ≤15μg/L             | Generalized aminosideruria           | ND a+                               |
| interferon-gamma release assays | -                | -                                    | PTH-intact                  | 24.39g/ml            | NAG                                  | 9.0 U/L* 8.0 U/L*                   |
| sputum culture              | no particular findings | ND                                  | IgG                         | 1.022mg/dL           | Bence Jones protein                   | - ND                                |
|                            |                  |                                       | IgA                         | 262mg/dL             | Na                                   | 57mEq/L 56mEq/L                     |
|                            |                  |                                       | IgM                         | 630mg/dL*            | K                                    | 21mEq/L 63.2mEq/L                   |
|                            |                  |                                       | IgG4                        | 14.0mg/dL            | CL                                   | 44mEq/L 31mEq/L                     |
|                            |                  |                                       | C3                          | 75mg/dL*             | urine Ca/Cr ratio                    | ND 0.21*                           |
|                            |                  |                                       | C4                          | 18mg/dL              | FSH (after loading bicarbonate)      | ND 8.0%*                           |
|                            |                  |                                       |                             |                      | FEP                                  | ND 56.6%*                           |
|                            |                  |                                       |                             |                      | %TRP                                 | ND 43.4%*                           |
|                            |                  |                                       |                             |                      | TmP/GFR                              | ND 0.95mg/dL*                       |
|                            |                  |                                       |                             |                      | FEUA                                 | 34.1%* 75.6%*                       |
|                            |                  |                                       |                             |                      | FEK                                  | 12%* 105.1%*                        |

Asterisks (*) indicate abnormal values.  
A-ADO2: alveolar-arterial oxygen difference, Ab: antibody, Ag: antigen, Alb: albumin, ALP: alkaline phosphatase, ALT: alanine aminotransferase, ANA: antinuclear antibody, APTT: activated partial thromboplastin time, AST: aspartate aminotransferase, Ba: basophils, β2MG: beta-2 microglobulin, BUN: blood urea nitrogen, Cr: creatinine, CRP: C-reactive protein, cGFR, estimated glomerular filtration rate, Eo: eosinophils, FECHO: fracion excretion of bicarbonate, FEK: fractional excretion of potassium, FEP: fractional excretion of phosphate, FEUA: fractional excretion of uric acid, gbl: globulin, GLU: casual blood glucose, γGTP: gamma-glutamyl transpeptidase, Hb: hemoglobin, HBC: hepatitis B core, HBs: hepatitis B surface, HCV: hepatitis C virus, HIV: human immunodeficiency virus, Ht: hematocrit, Ig: immunoglobulin, LDH: lactate dehydrogenase, LDL-C: low-density lipoprotein cholesterol, Ly: lymphocytes, Mon: monocytes, NAG: N-acetyl-beta-D-glucosaminidase, ND: no data, Neu: neutrophils, NSGSP: National Glycohemoglobin Standardization Program, PTH: parathyroid hormone, PT-INKR: prothrombin time-international normalized ratio, SpD2: saturation of percutaneous oxygen, T-Chr: total cholesterol, T-Bil: total bilirubin, TP: total protein, TRP: tubular re-absorption of phosphate, TSH: thyroid-stimulating hormone, TmP/GFR: tubular maximum of phosphate, T4: thyroxine 4, UA: uric acid, 1, 25 (OH)2VD3, 1, 25-dihydroxy vitamin D3.
Figure 1. Computed tomography findings. (a) Abdominal computed tomography showed left kidney stones (arrows). (b, c) Chest computed tomography showed bilateral multifocal peribronchial infiltrates that mainly existed in the lower lobes. (d) Subpleural consolidations were also seen in the lower lobes. (e) Bilateral multifocal peribronchial shadows vanished after the first steroid therapy.

Figure 2. Histological findings in the kidney. (a, b) Light microscopy showed lymphocyte infiltration within the interstitial compartment and between tubules [a: Hematoxylin and Eosin (H&E) staining ×100, b: Azan Mallory ×100]. (c) Lymphocytes and plasma cells infiltrated the interstitium (H&E staining ×400).

abnormality in the liver or biliary system. A liver biopsy was not conducted at her request. She might have had asymptomatic primary biliary cholangitis but did not satisfy the criteria without a liver biopsy (11). She suffered bone
pain again and needed crutches to walk. CT revealed bone fractures in the ribs, although she had no history of relevant trauma (Fig. 6a-c). A few steps of running led to left femoral neck fracture (Fig. 6d), but she did not show any signs of pulmonary involvement.

Finally, her TIN was diagnosed as TIN with antimitochondrial antibody; she started a third round of oral prednisolone therapy (20 mg/day) about 2 years after the second round. After a few months, her eGFR increased to 34.7 mL/min/1.73 m², her serum phosphorus increased to 3.9 mg/dL, her ALP and U-β2MG decreased, and her IgM decreased to 147 mg/dL. Her bone pain was relieved. After three months, she did not need crutches to walk anymore, and the dose of prednisolone was tapered. Eight months after she started the third round of prednisolone therapy, azathioprine (75 mg/day) was added. At this time (about eight years after the first round of prednisolone therapy), no signs of recurrence had been detected (Fig. 4).

Figure 3. Histological findings in the kidney by the immunoenzyme method with formalin-fixed paraffin-embedded sections. (a, b) IgG-positive plasma cells were not detected in the interstitial compartment (IgG staining a: ×100, b: ×400). (c, d) IgM-positive plasma cells were not seen (IgM staining c: ×100, d: ×400). (e, f) Some of the cells in the interstitium were CD138-positive (CD138 staining e: ×100, f: ×400).
Figure 4. Clinical course. ALP: alkaline phosphatase, AZA: azathioprine, eGFR: estimated glomerular filtration rate, ND: no data, PSL: prednisolone, U-β2MG: urine β2 microglobulin

Figure 5. Recurrence of lung involvement. (a-c) Computed tomography showed bilateral multifocal reticulonodular, reticulofibrotic infiltrates with ground-glass opacification mainly in the lower lobes. (d) After the second round of steroid therapy, the bilateral shadows disappeared.
Discussion

Proteinuria was one of the two reasons the present patient was referred to our hospital, and her urinary protein consisted largely of low-molecular-weight protein. TIN with AMAs has been reported to respond to glucocorticoids. However, some cases have relapsed after glucocorticoid therapy or did not respond to glucocorticoids at all. Macdougall et al. reported a 50-year-old woman treated with prednisolone (40 mg for 7 weeks, then reduced to 5 mg for 4 weeks); her creatinine clearance recovered from 28 to 68 mL/minute. After the glucocorticoid therapy was ended, the creatinine clearance decreased to 26 mL/minute (1). Lino et al. reported 2 cases of a 51- and 68-year-old woman. Both were treated with steroids (0.5 mg/kg/day). In the younger case, the serum creatinine (1.77 mg/dL) slightly decreased to 1.35 mg/dL but then increased to 1.58 mg/dL after the 6-month steroid therapy regimen had ended. In the older case, the serum creatinine (1.3 mg/dL) did not improve at all but increased to 2.29 mg/dL (2). The present case responded to prednisolone and relapsed twice after tapering prednisolone. We tested for AMA only after the second relapse. As in the cases described above, TIN with AMAs can relapse after glucocorticoid therapy. Therefore, when tapering prednisolone for a third time, azathioprine was added. Mycophenolate mofetil and rituximab are other viable options, but the most suitable treatment for TIN with AMAs has not yet been established (12). To our knowledge, this is the first reported case of TIN with AMAs treated with azathioprine and glucocorticoids. We believe that the accumulation of similar cases for long periods is needed to determine the optimal initial dose of glucocorticoids, the optimal period of treatment, the need for a maintenance dose of glucocorticoids, and the effect of immunosuppressants.

TIN with IgM-positive cells is a new histologic entity with clinical features similar to the present case, such as RTA, Fanconi syndrome, high serum IgM levels and AMA positivity and one of its features is IgM-positive plasma cell (CD138-positive cell) infiltration (13-15). CD138 is an excellent marker of plasma cells (16, 17), but it is also expressed in some B-chronic lymphocytic leukemia (18) and in body cavity-based lymphomas (primary effusion lymphomas) (19). Our case did not show clinical aspects of either of these entities. However, IgG- and IgM-positive cells were not detected in our case. IgE-containing plasma cells in TIN were reported using immunofluorescence in a case of drug (phenobarbitone)-induced TIN (20) and in a case of TIN with polyarteritis nodosa (21); IgA plasma cell infiltration in TIN was also reported in a patient with hepatocellular carcinoma as a control (22). However, due to the anatomical pathology, including the findings of case reports, it is impossible to avoid false positive and false negative findings (23). Our IgG and IgM staining findings may have been due to technical errors, or the plasma cells in our case might contain other immunoglobulins, such as IgE and IgA, rather
than IgG and IgM. We were unable to conclusively determine the type of immunoglobulin in those plasma cells, and our case was not diagnosed as TIN with IgM-positive plasma cells but as TIN with AMAs. The difference between TIN with IgM-positive plasma cells and TIN with AMAs is not clearly defined at present. While TIN with IgM-positive cells and TIN with AMAs do not always coincide with primary biliary cholangitis (PBC) (3, 14), IgM-positive plasma cell infiltration in the liver is useful for differentiating PBC from autoimmune hepatitis (24). However, the usefulness of IgG and IgM staining was reported to be limited because of the low sensitivity of IgM staining, the equivocal IgM staining, and the difficulty associated with interpreting immunostaining (25). As for the progression of TIN with those plasma cells in the kidney, serum immunoglobulin might also have some association with the progression of TIN. In our case and other cases of TIN with IgM-positive plasma cells (13, 15), the serum IgM level increases when TIN worsened. However, PBC has been reported to coexist with acquired total IgG deficiency (26), selective IgA deficiency (27), and common variable immunodeficiency, in which the serum levels of IgG, IgA, and IgM are decreased (28). Immunoglobulin-mediated mechanisms might not be essential, even for the progression of PBC. The underlying mechanisms and pathogenesis of plasma cells’ involvement in the kidney and high serum IgM levels are not clear in TIN with AMAs/IgM-positive plasma cells.

Pulmonary involvement was another reason the present patient was referred to our hospital. Mason et al. reported five cases of fibrosing alveolitis with complete renal tubular acidosis and four cases of fibrosing alveolitis with incomplete RTA (29). Fibrosing alveolitis was a previously employed term used to describe interstitial pneumonia; autoimmune processes have reportedly been involved in the pathogenesis of some cases (30). In Mason’s report, some patients showed high serum IgM levels. Furthermore, AMAs were positive in some of them, and all of them had Sjögren’s syndrome and/or PBC. The renal and pulmonary abnormalities were assumed to be a part of a systematic disorder capable of affecting many organs. The authors were interested in the possible association between pulmonary involvement and hyperglobulinemic RTA alone. While both Sjögren’s syndrome (31) and PBC (32) can be complicated with pulmonary involvement, proximal and distal RTA are caused by TIN (33). IgM and/or AMAs might be pathophysiologically related to pulmonary involvement and TIN/RTA. The renal and pulmonary abnormalities might be part of a systemic/autoimmune disorder capable of affecting many organs. In the present case, the TIN and pulmonary involvement seemed to take a similar clinical course, except for at the final relapse. As Mason et al. were interested in the possible association between pulmonary involvement and hyperglobulinemic RTA, the interstitial pneumonia in this case was assumed to be related to hyperglobulinemia RTA, which is one of the main features of TIN with AMAs. However, Mason et al. did not mention the coexistence of TIN in their cases.

Furthermore, pulmonary involvement has not been reported in TIN with AMAs/IgM-positive plasma cells thus far (1-5, 13-15). The absence of Sjögren’s syndrome, but a definite finding for PBC, TIN with AMAs in this case suggested for the first time a possible association between lung involvement and TIN with AMAs. We did not analyze the inflammatory cells in the patient’s spontaneous and/or induced sputum, nor did we test the levels of pulmonary surfactant proteins SP-A, SP-D, and KL-6.

In summary, we reported a case of TIN with AMA M2 antibody, high serum IgM levels, distal RTA, and Fanconi syndrome that was treated effectively with prednisolone and azathioprine. Notably, our case had pulmonary involvement. Care should be taken concerning the possibility of pulmonary involvement in patients diagnosed with TIN with AMAs. In our case, interstitial pneumonia relapsed once, and TIN relapsed twice. These findings underscore the need for a maintenance dose of glucocorticoids and immunosuppressants in cases of TIN with AMAs.

The authors state that they have no Conflict of Interest (COI).

Ethical approval: This article does not contain any studies with human participants or animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent: Informed consent was obtained from all individual participants included in this study.

References
1. Macdougall IC, Isles CG, Whitworth JA, More IA, MacSween RN. Interstitial nephritis and primary biliary cirrhosis: a new association? Clin Nephrol 27: 36-40, 1987.
2. Lino M, Binaut R, Noel LH, et al. Tubulointerstitial nephritis and Fanconi syndrome in primary biliary cirrhosis. Am J Kidney Dis 46: e41-e46, 2005.
3. Hara M, Miyazawa R, Takagi A, et al. (Case of fanconi syndrome positive for anti-M2 antibodies revealed by severe hypokalemia and multiple bone fracture). Nihon Jinzo Gakkai Shi 53: 719-725, 2011.
4. Sacki T, Nakajima A, Ito T, et al. Tubulointerstitial nephritis and Fanconi syndrome in a patient with primary Sjögren’s syndrome accompanied by antimitochondrial antibodies: A case report and review of the literature. Mod Rheumatol 28: 897-900, 2018.
5. Morita M, Yamaguchi Y, Masuyama S, et al. Anti-mitochondria antibody-related tubulointerstitial nephritis accompanied by severe hypokalemic paralysis. CEN Case Rep 8: 119-124, 2019.
6. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61: 554-558, 2002.
7. Fujibayashi T, Sugai S, Miyasaka N, et al. Revised Japanese criteria for Sjögren’s syndrome (1999): availability and validity. Mod Rheumatol 14: 425-434, 2004.
8. Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism Classifi-
